Abstract
Background Urothelial carcinoma of the bladder (UBC) comprises several molecular subtypes, which are associated with different targetable therapeutic options. However, if and how these associations extend to the rare upper tract urothelial carcinoma (UTUC) remains unclear.
Objective Identifying UTUC protein-based subtypes and developing a deep-learning (DL) workflow to predict these subtypes directly from histopathological H&E slides.
Design, Setting, and Participants Subtypes in a retrospective cohort of 163 invasive samples were assigned on the basis of the immunohistochemical expression of three luminal (FOXA1, GATA3, CK20) and three basal (CD44, CK5, CK14) markers. DL model building relied on a transfer-learning approach.
Outcome Measurements and Statistical Analysis Classification performance was measured via repeated cross-validation, including assessment of the area under the receiver operating characteristic (AUROC). The association of the predicted subtypes with histological features, PD-L1 status, and FGFR3 mutation was investigated.
Results and Limitations Distinctive luminal and basal subtypes were identified and could be successfully predicted by the DL (AUROC 95th CI: 0.62-0.99). Predictions showed morphology as well as presence of FGFR3-mutations and PD-L1 positivity that were consistent with the predicted subtype. Testing of the DL model on an independent cohort highlighted the importance to accommodate histological subtypes.
Conclusions Our DL workflow is able to predict protein-based UTUC subtypes directly from H&E slides. Furthermore, the predicted subtypes associate with the presence of targetable genetic alterations.
Patient Summary UTUC is an aggressive, yet understudied, disease. Here, we present an artificial intelligence algorithm that can predict UTUC subtypes directly from routine histopathological slides and support the identification of patients that may benefit from targeted therapy.
Competing Interest Statement
Bernd Wullich: Speaker's honoraria from MSD and Janssen-Cilag. Markus Eckstein: Personal fees, travel costs and speaker's honoraria from MSD, AstraZeneca, Janssen-Cilag, Cepheid, Roche, Astellas, Diaceutics; research funding from AstraZeneca, Janssen-Cilag, STRATIFYER, Cepheid, Roche, Gilead; advisory roles for Diaceutics, MSD, AstraZeneca, Janssen-Cilag, GenomicHealth and Owkin. Arndt Hartmann: honoraria for lectures for Abbvie, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Ipsen, Janssen, Lilly, MSD, Nanostring, Novartis, Roche, and 3DHistotech; advisory role for Abbvie, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Gilead, Illumina, Ipsen, Janssen, Lilly, MSD, Nanostring, Novartis, Qiagen, QUIP GmbH, Roche, and 3DHistotech; and research funding from AstraZeneca, Biontech, Cepheid, Gilead, Illumina, Janssen, Nanostring, Qiagen, QUIP GmbH, Roche, and STRATIFYER. Joost L. Boormans: Consultancy (all paid to Erasmus MC): Janssen, Merck, MSD, BMS, AstraZeneca; Research support: Merck/Pfizer, Janssen, MSD. Veronika Bahlinger: Personal fees, travel costs and speaker's honoraria from MSD; research funding from Gilead.
Funding Statement
This study was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation; SFB TRR 305 - Z01 to FF and Z02 to AH; SFB TRR 374 - INF1 to FF), by the Federal Ministry of Education and Research (BMBF) and the Dutch Cancer Society (KWF kankerbestrijding) in the framework of the ERA-NET TRANSCAN-2 initiative (to AH and JB), by the IZKF FAU Erlangen-Nuernberg (step 2 clinician scientist program to ME), by the Else Kroener-Fresenius-Stiftung (grant number: 2020_EKEA.129 to ME), by the Bavarian Center of Cancer Research (BZKF; Young Clinical Scientist Fellowship to ME), and the Federal Ministry of Education and Research (BMBF) 01KD2211B (ID: 100577017 to ME).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of the Friedrich-Alexander University Erlangen-Nuernberg (No. 329_16B) and the Erasmus Medical Centre Rotterdam (METC 2017-227 NL60919.078.17) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
